Table 2.

N100 peak amplitude and latency by group.

	HC (n = 236)	CHR (n = 552)	CHR
			CHR-NC (n =225)	CHR-C (n = 73)
Cz electrode
N100 amplitude, μV (mean ± SD)
Standard stimuli	−4.50 ± 2.40	−4.16 ± 2.44	−4.26 ± 2.64	−3.66 ± 2.16
Novel stimuli	−6.12 ± 4.31	−5.80 ± 4.45	−6.28 ± 4.64	−4.43 ± 3.80
Target stimuli	−6.59 ± 3.58	−6.32 ± 3.77	−6.56 ± 3.96	−6.24 ± 3.76
N100 latency, ms (mean ± SD)
Standard stimuli	97.85 ± 9.77	98.85 ± 10.82	97.98 ± 11.44	98.62 ± 9.39
Novel stimuli	105.41 ± 15.45	105.44 ± 15.55	106.06 ± 15.89	103.33 ± 14.13
Target stimuli	97.10 ± 12.01	97.76 ± 13.17	98.39 ± 14.12	98.33 ± 12.83
Fz electrode
N100 amplitude, μV (mean ± SD)
Standard stimuli	−4.55 ± 2.47	−4.24 ± 2.56	−4.35 ± 2.84	−3.73 ± 2.25
Novel stimuli	−5.27 ± 4.04	−4.68 ± 4.08	−4.98 ± 4.18	−4.19 ± 4.10
Target stimuli	−7.06 ± 3.89	−7.08 ± 3.85	−7.42 ± 4.04	−7.09 ± 4.20
N100 latency, ms (mean ± SD)
Standard stimuli	100.47 ± 10.43	102.24 ± 11.96	101.42 ± 12.36	101.68 ± 10.82
Novel stimuli	104.45 ± 14.77	103.03 ± 14.42	102.76 ± 14.61	103.81 ± 14.83
Target stimuli	98.58 ± 12.00	100.92 ± 13.89	101.58 ± 14.57	99.64 ± 15.28

HC = Healthy control subjects; CHR = Clinical High Risk subjects (at Baseline).

CHR-NC = Subjects who did not converted to psychosis by 2 years.